This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

UKPDS 39 trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The UKPDS 39 trial aimed to determine whether a beta-blocker or an angiotensin converting enzyme inhibitor had a specific advantage or disadvantage in the prevention of macrovascular and microvascular complications of type 2 diabetes.

The trial randomly assigned patients to tight control of blood pressure (aim <150/85 mmHg) with captopril or atenolol.

Reference:

  • 1) UK Prospective Diabetes Study Group (1998). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 39. BMJ, 317, 713-720.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page